<table class="naaccr-summary-table naaccr-borders">
    <tr>
        <th class="naaccr-summary-header naaccr-borders">Item #</th>
        <th class="naaccr-summary-header naaccr-borders">Length</th>
        <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
        <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
    </tr>
    <tr>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">3941</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">NAACCR</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2021</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">21</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.nrasMutationalAnalysis<br/><br/>


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div>
<div class='content chap10-para'>NRAS is a signaling intermediate in the growth receptor pathway. Certain NRAS mutations predict poor response to anti-EGFR therapy in patients with metastatic colorectal cancer.</div>
<div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div>
<div class='content chap10-para'>NRAS mutational analysis is recommended in clinical guidelines for patients with metastatic colon cancer who are being considered for anti-EGFR therapy. It is a new data item for cases diagnosed 01/01/2021+.</div>
<div class='content chap10-para'><strong>Codes</strong></div>
<div class='content chap10-para'>
    <table>
        <tr class='code-row'>
            <td class='code-nbr'>0</td>
            <td class='code-desc'>Normal<br/>
                NRAS negative; NRAS wild type<br/>
                Negative for (somatic) mutations, no alterations, no (somatic) mutations identified, not present, not detected
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>1</td>
            <td class='code-desc'>Abnormal (mutated)/detected in codon(s) 12, 13, and/or 61</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>2</td>
            <td class='code-desc'>Abnormal (mutated)/detected, codon(s) specified but not in codon(s) 12, 13, or 61</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>4</td>
            <td class='code-desc'>Abnormal (mutated), NOS, codon(s) not specified</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>7</td>
            <td class='code-desc'>Test ordered, results not in chart</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>8</td>
            <td class='code-desc'>Not applicable: Information not collected for this case<br/>
                If this information is required by your standard setter, use of code 8 may result in an edit error.
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>9</td>
            <td class='code-desc'>Not documented in medical record<br/>
                NRAS not assessed or unknown if assessed
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'></td>
            <td class='code-desc'></td>
        </tr>
    </table>
</div>
<div class='content chap10-para'>Each Site-Specific Data Item (SSDI) applies only to selected primary
    sites, histologies, and years of diagnosis. Depending on applicability
    and standard-setter requirements, SSDIs may be left blank.
</div>